US · GH
Guardant Health, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Palo Alto, CA 94063
- Website
- guardanthealth.com
Price · as of 2025-12-31
$87.60
Market cap 12.32B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $57.64 | -34.2% |
| Intrinsic Value(DCF) | $48.76 | -44.34% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $62.92 | $57.25 | $2,542.48 | $0.68 | $0.00 |
| 2019 | $78.13 | $69.48 | $62,649.93 | $4.60 | $0.00 |
| 2020 | $142.96 | $78.61 | $1,363.43 | $0.27 | $0.00 |
| 2021 | $54.40 | $35.80 | $46.01 | $0.00 | $0.00 |
| 2022 | $25.01 | $21.45 | $0.00 | $0.00 | $0.00 |
| 2023 | $19.73 | $25.82 | $0.00 | $0.00 | $0.00 |
| 2024 | $39.32 | $35.47 | $0.01 | $0.00 | $0.00 |
| 2025 | $92.23 | $57.64 | $3.87 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Guardant Health, Inc.'s (GH) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $57.64
- Current price
- $87.60
- AI upside
- -34.2%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$48.76
-44.34% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GH | Guardant Health, Inc. | $87.60 | 12.32B | -34% | -44% | — | — | -27.78 | -116.44 | 11.77 | -32.21 | — | -57.11 | 64.46% | -44.43% | -42.39% | 348.42% | -117.88% | -23.79% | -16.94 | -111.96 | 4.84 | 4.42 | -3.49 | -674.00% | 3288.00% | -1523.00% | -2.02% | -0.61 | -63.16% | 0.00% | 0.00% | 0.12% | -27.61 | -51.68 | 12.26 | 1.67 |
| ASND | Ascendis Pharma A/S | $233.50 | 14.33B | -41% | +2,942% | — | — | -57.24 | -77.03 | 18.12 | -112.32 | — | -75.32 | 85.08% | -18.92% | -31.67% | 163.18% | -92.10% | -17.65% | -5.35 | -1.69 | 1.04 | 0.72 | -2.24 | -4456.00% | 9022.00% | -11418.00% | 0.35% | 0.05 | 30.69% | 0.00% | 0.00% | 0.46% | -97.73 | 293.28 | 18.49 | 2.47 |
| BBIO | BridgeBio Pharma, Inc. | $66.48 | 12.89B | -12% | +7,582% | — | — | -17.82 | -6.22 | 25.73 | -22.38 | -56.40 | -6.14 | 94.37% | -113.35% | -145.26% | 40.90% | 321.74% | -78.14% | -1.31 | -10.72 | 2.62 | 2.52 | -3.21 | 3160.00% | 12626.00% | -1431.00% | -3.46% | -1.55 | 252.72% | 0.00% | 0.00% | 0.37% | -26.46 | -33.69 | 30.00 | -4.02 |
| EHC | Encompass Health Corporat… | $107.88 | 10.85B | -27% | -39% | -66% | -6% | 19.15 | 3.38 | 1.83 | 7.87 | 78.34 | 6.82 | 21.72% | 17.74% | 9.54% | 21.47% | 20.72% | 8.33% | 0.08 | 8.55 | 1.08 | 0.83 | 0.14 | 2444.00% | 1046.00% | 2190.00% | 4.04% | 1.41 | 10.83% | 0.65% | 12.50% | 24.52% | 10.50 | 25.17 | 1.86 | 3.05 |
| EXAS | Exact Sciences Corporatio… | $103.38 | 19.73B | -34% | -59% | — | — | -93.78 | 8.12 | 6.01 | 171.91 | — | -21.99 | 69.69% | -3.05% | -6.40% | -8.66% | -2.45% | -3.53% | 1.05 | -3.01 | 2.43 | 1.97 | 12.79 | -8032.00% | 1769.00% | 37860.00% | 1.83% | 0.77 | 8.83% | 0.00% | 0.00% | 3.01% | -212.55 | 59.02 | 6.49 | 2.94 |
| ICLR | ICON Public Limited Compa… | $108.14 | 8.26B | +89% | -31% | -50% | -11% | 19.44 | 1.62 | 1.86 | 11.80 | 67.55 | -4.98 | 29.42% | 13.26% | 9.56% | 8.44% | 7.88% | 4.67% | 0.38 | 4.63 | 1.26 | 1.21 | 1.96 | 2878.00% | 199.00% | 963.00% | 7.27% | 0.46 | 8.81% | 0.00% | 0.00% | 6.47% | 16.81 | 16.50 | 2.23 | 2.24 |
| IONS | Ionis Pharmaceuticals, In… | $81.15 | 13.14B | -40% | -60% | — | — | -34.38 | 26.82 | 13.89 | -46.25 | — | 26.82 | 98.31% | -40.47% | -40.36% | -70.80% | -221.28% | -11.69% | 5.78 | -5.23 | 1.95 | 1.79 | -8.56 | -2171.00% | 3387.00% | -4141.00% | -2.44% | -0.18 | -185.38% | 0.00% | 0.00% | 0.00% | -34.72 | -41.44 | 14.05 | 1.95 |
| QGEN | Qiagen N.V. | $49.80 | 10.26B | +6% | -52% | -77% | -45% | 23.90 | 2.69 | 4.86 | 14.93 | 5.47 | 14.69 | 61.79% | 24.90% | 20.33% | 11.57% | 10.79% | 7.09% | 0.44 | 15.65 | 3.90 | 2.93 | 1.14 | 43684.00% | 565.00% | -1049.00% | 4.46% | 1.28 | 10.85% | 0.53% | 12.80% | 1.82% | 20.58 | 23.63 | 5.12 | 3.92 |
| RVTY | Revvity, Inc. | $98.31 | 11.15B | +3% | -60% | -88% | -75% | 44.87 | 1.49 | 3.79 | 20.25 | — | -6.33 | 53.08% | 12.49% | 8.46% | 3.23% | 3.28% | 1.96% | 0.48 | 3.87 | 1.68 | 1.25 | 3.92 | -1369.00% | 367.00% | -617.00% | 4.70% | 0.44 | 5.17% | 0.30% | 13.60% | 7.89% | 37.63 | 26.40 | 4.70 | 1.74 |
| SOLV | Solventum Corporation | $74.20 | 12.87B | +72% | -56% | -45% | +7% | 8.17 | 2.52 | 1.53 | 6.62 | 3.68 | -3.91 | 53.47% | 26.20% | 18.69% | 38.86% | 20.41% | 10.82% | 1.00 | 6.29 | 1.23 | 0.61 | 1.63 | 22174.00% | 86.00% | -10124.00% | -0.08% | 0.12 | -0.10% | 0.00% | 0.00% | 24.32% | 7.73 | -1686.63 | 2.03 | 2.15 |
| VTRS | Viatris Inc. | $14.93 | 17.2B | +55% | -58% | — | — | -5.23 | 1.25 | 1.29 | -79.59 | -1.12 | -2.57 | 35.06% | -18.62% | -24.58% | -21.08% | -8.56% | -8.93% | 0.98 | -5.65 | 5.06 | 2.25 | -33.11 | 46604.00% | -298.00% | -201.00% | 10.54% | 1.20 | 6.49% | 3.05% | -16.00% | 8.39% | -11.82 | 16.25 | 2.20 | 0.88 |
About Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
- CEO
- Helmy Eltoukhy
- Employees
- 2K
- Beta
- 1.65
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($48.76 ÷ $87.60) − 1 = -44.34% (DCF, example).